CINCINNATI--(BUSINESS WIRE)--Mar. 20, 2018--
Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company
focused on advancing first-in-class treatments for ocular diseases,
today announced that Chief Executive Officer, Stephen Hoffman, M.D.,
Ph.D., will present at the 17th Annual Needham Healthcare
Conference on Tuesday, March 27, 2018 at 3:00 p.m. Eastern Time in New
York, NY. Dr. Hoffman will provide a corporate overview and business
update.
The presentation will be webcast live and may be accessed by visiting
Aerpio's website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class treatments for ocular diseases. The Company’s
lead compound, AKB‐9778, is a small molecule activator of the Tie2
pathway and is in clinical development for the treatment of
non-proliferative diabetic retinopathy. For more information please
visit www.aerpio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180320005716/en/
Source: Aerpio Pharmaceuticals, Inc.
Investor & Media:
Aerpio
Pharmaceuticals, Inc.
Michael Rogers, 513-985-1958
Chief
Financial Officer
or
Burns McClellan, on behalf of Aerpio
Pharmaceuticals, Inc.
Media:
Justin
Jackson
jjackson@burnsmc.com
or
Investors:
Ami
Bavishi
abavishi@burnsmc.com
